In a collaboration with pharma company Sprint Bioscience, researchers at the Luxembourg Institute of Health (LIH), have developed an innovative approach to improve cancer immunotherapy by turning “cold” tumours “hot”.
“Cold”, immune-desert tumours are classically immunotherapy-resistant. “Hot” or inflamed tumours, by contrast, are infiltrated by the immune system and responsive to immunotherapy. At the epicentre of this strategy lies a novel molecule developed by Sprint Bioscience, SB02024, which was shown to successfully inhibit autophagy, a process of “self-digestion” that allows cancer cells to acquire nutrients to sustain their growth.
Immune checkpoint inhibitors (ICI), exemplified by anti-PD-1, are immunotherapeutic drugs that act by removing the “brakes” on the immune system and unleashing an immune attack on cancer cells.
These drugs are very promising for the treatment of many cancers. However, only relatively few cancer patients show significant therapeutic benefits when treated with ICI alone. Therefore, there is a strong clinical need to design combinatorial therapies that increase the response rates and extend the use of ICI to a larger number of patients and tumour types.
One of the major causes of tumour unresponsiveness to ICI is the poor infiltration of cytotoxic immune cells into the tumour bed. Therefore, approaches that drive immune cells into cold poorly infiltrated tumours would significantly enhance the therapeutic benefit of immunotherapy based on ICI.
In this context, the TIME group and Sprint Bioscience devised an innovative strategy to drive major cytotoxic immune cells into the tumour bed by inhibiting autophagy. Autophagy, a cellular “recycling” process, has also been associated with the evasion of cancer cells from immune surveillance.
Specifically, the scientists leveraged on several molecules and techniques, including Sprint Bioscience’s lead compound SB02024, that act against Vps34, a key protein involved in initiating the process of autophagy.
The researchers used preclinical mouse models to evaluate the effects of genetically and pharmacologically targeting Vps34 on tumour growth and mice survival. Interestingly, they found that inhibition of autophagy led to an increase in the release of CCL5 and CXCL10, two pro-inflammatory cytokines involved in the recruitment of cytotoxic immune cells such as Natural Killers (NK), macrophages and T-cells into the tumour microenvironment.
This infiltration resulted in reduced tumour growth and prolonged survival in both melanoma and colorectal tumour-bearing mice. These findings highlighted Vps34 inhibitors as valuable drugs making tumours eligible or responsive to immunotherapy based on ICI. Furthermore, Dr Janji’s team showed that combining the Vps34 inhibitor SB02024 with anti-PD-1 significantly improves the efficacy of this ICI in resistant melanoma and colorectal cancer.
Based on their preclinical results, the scientists also established a “Vps34 response signature”. Using this signature they were able to stratify 470 melanoma patients into three groups exhibiting a high, intermediate, and low expression level of “Vps34 response signature”.
The three groups correspond to patients displaying “hot”, “intermediate” and “cold tumours”, respectively. The team showed that the overall and disease-free survival of patients displaying a high “Vps34 response signature” (“hot tumour”) is significantly better compared to those bearing a low “Vps34 response signature” (“cold tumour”).
“Our results brought forward the potential of inhibiting autophagy-related protein Vps34 as an innovative combinatorial approach to extend the therapeutic benefit of anti-PD-1 to melanoma and colorectal patients who are not responding to or not eligible for this ground-breaking immunotherapy. Furthermore, our findings provide the first proof of concept supporting the design of innovative clinical trials using Vps34 inhibitors in combination with anti-PD-1”, concludes Dr Janji.
The study, co-authored by Dr Bassam Janji (Tumor Immunotherapy and Microenvironment (TIME) research group led by Dr Bassam Janji at the Luxembourg Institute of Health (LIH) Department of Oncology (DONC)) and Dr Guy Berchem (LIH/CHL), was published on 29 April 2020 in the journal Science Advances, with the full title ‘Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy’. It was carried out in collaboration with Sprint Bioscience (Sweden), the Centre Hospitalier de Luxembourg (CHL), the Karolinska Institute (Sweden) and the University of Pennsylvania (USA).
The study was supported by grants from the FNR (C18/BM/12670304/COMBATIC), FNRS Televie, Fondation Cancer, Foundatioun Kriibskrank Kanner, Janssen Cilag Pharma, Action LIONS Vaincre le Cancer Luxembourg and the Swedish Foundation for Strategic Research.